Clinical Trial Update: Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports on serum biomarkers to predict response to Angiotensin II in septic shock, and notes the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock
• Vasodilatory Shock

Drugs mentioned

• Giapreza (Angiotensin II)

Snippet

Sponsor: University of New Mexico | Conditions: Septic Shock, Vasodilatory Shock | Phase 4 | Status: COMPLETED